Laffont CM - Search Results

1

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators. Haight BR, et al. Among authors: laffont cm. Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18. Lancet. 2019. PMID: 30792007 Clinical Trial.

2

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Laffont CM, et al. J Clin Pharmacol. 2016 Jul;56(7):806-15. doi: 10.1002/jcph.665. Epub 2016 Mar 11. J Clin Pharmacol. 2016. PMID: 26479717 Clinical Trial.

3

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.

Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM. Dong R, et al. Among authors: laffont cm. Drugs R D. 2019 Sep;19(3):255-265. doi: 10.1007/s40268-019-0277-9. Drugs R D. 2019. PMID: 31197606 Free PMC article. Clinical Trial.

4

Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, Laffont CM. Ivaturi V, et al. Among authors: laffont cm. Br J Clin Pharmacol. 2017 Jul;83(7):1476-1498. doi: 10.1111/bcp.13246. Epub 2017 Mar 31. Br J Clin Pharmacol. 2017. PMID: 28133766 Free PMC article. Clinical Trial.

5

Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Laffont CM, et al. Clin Pharmacokinet. 2014 Jun;53(6):533-43. doi: 10.1007/s40262-014-0132-7. Clin Pharmacokinet. 2014. PMID: 24464285 Clinical Trial.

6

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.

Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Jones AK, et al. Among authors: laffont cm. Clin Pharmacokinet. 2021 Apr;60(4):527-540. doi: 10.1007/s40262-020-00957-0. Epub 2020 Nov 2. Clin Pharmacokinet. 2021. PMID: 33135125 Free PMC article. Clinical Trial.

7

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.

Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Laffont CM, et al. J Clin Pharmacol. 2015 Jan;55(1):93-103. doi: 10.1002/jcph.366. Epub 2014 Jul 23. J Clin Pharmacol. 2015. PMID: 25043337 Clinical Trial.

8

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder.

Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA. Schmith VD, et al. Among authors: laffont cm. Clin Pharmacol Ther. 2019 Sep;106(3):576-584. doi: 10.1002/cpt.1406. Epub 2019 Apr 8. Clin Pharmacol Ther. 2019. PMID: 30801681 Free PMC article.

9

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.

Kranzler HR, Lynch KG, Crist RC, Hartwell E, Le Moigne A, Laffont CM, Andorn AC. Kranzler HR, et al. Among authors: laffont cm. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):89-96. doi: 10.1093/ijnp/pyaa069. Int J Neuropsychopharmacol. 2021. PMID: 32920647 Free PMC article. Clinical Trial.

10

Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.

Kharidia J, Howgate EM, Laffont CM, Liu Y, Young MA. Kharidia J, et al. Among authors: laffont cm. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1064-1074. doi: 10.1002/cpdd.934. Epub 2021 Mar 22. Clin Pharmacol Drug Dev. 2021. PMID: 33750027 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters